Researchers call for urgent exploration of methods to cool Earth
It is already obvious that some governments are not acting fast enough to keep the planet's temperature from rising dangerously. While it is essential to continue to concentrate on reducing methane and carbon dioxide emissions as quickly as possible, other methods of cooling the planet need to be urgently explored, according to academics at the University of Cambridge's engineering department.
Related: UK scientists to launch outdoor geoengineering experiments
One of the problems is that many of the ideas put forward so far, including injecting sulphates into the atmosphere to reflect sunlight back into space, could do more harm than good. This is because sulphates cause acid rain and interfere with rainfall patterns.
To avoid controversy researchers are experimenting with alternatives to sulphates, substances that reflect sunlight but are benign. They will hoist them into the stratosphere using weather balloons then recover them to see what changes this exposure causes. No materials will be released but their cooling effect and whether they could otherwise be harmless can be gauged.
Other ideas like drilling holes in the Arctic ice in the winter and pumping seawater over existing ice floes in below freezing air temperatures to thicken them are also being tried, along with spraying seawater to form clouds over the ocean, also to reflect sunlight. If these ideas are otherwise harmless, and work, they might yet save us.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
Not All Ritalin Is Created Equal: Why Some Generics Fail to Work
Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road. Researchers tested how generic Ritalin and other versions of the drug known as methylphenidate dissolve and found some dissipated much more quickly or slowly than they should have, according to a study, the final version of which is set to be published in the Journal of the American Academy of Child and Adolescent Psychiatry.
Medscape
2 hours ago
- Medscape
ICU Skin Decolonisation May Raise Resistant Infections
Universal skin decolonisation of patients admitted to intensive care units (ICU) may not improve infection control. New research led by the University of Aberdeen indicated that it might increase meticillin-resistant Staphylococcus epidermidis (MRSE) bloodstream infections in vulnerable patients. Hospital-associated infections cause significant morbidity and mortality, with critically ill patients in ICUs at particularly high risk. Surveillance figures from English ICUs show an ICU-associated bloodstream infection rate of 3.5 per 1000 bed-days for stays of two nights or more in the year to March 2024. Over 25% of patients with these infections die within 30 days. Reasons for the increased infection rate in ICUs include high antibiotic use leading to significant skin flora colonisation by resistant bacteria. Invasive procedures including indwelling catheters and the insertion of intravascular devices are independently associated with meticillin-resistant Staphylococcus aureus (MRSA) colonisation and infection. Need for a New Infection Control Approach Decolonisation protocols were introduced in the 1990s to curb rising nosocomial MRSA infections due to MRSA. Nationwide infection control programmes since the mid-2000s led to sharp declines in MRSA rates in NHS hospitals over the next decade. One UK-wide study in ICU patients between 2007 and 2016 showed a 78% decrease in bloodstream infections overall and a 97% reduction in MRSA bloodstream infections. However, data from the National Institute for Health and Care Research show this decline plateaued after 2012. Rates have subsequently been largely static, suggesting the need for a new approach. Routine ICU decolonisation typically involves chlorhexidine skin disinfection combined with nasal mupirocin. The Aberdeen team noted conflicting evidence on chlorhexidine's effectiveness. They also raised concerns that biocide skin and mucous membrane decolonisation might lead to reduced susceptibility to chlorhexidine and selection for multidrug-resistant pathogens. Study Compares Universal and Targeted Decolonisation The researchers compared universal versus targeted skin and nasal decolonisation in ICU patients at two Scottish hospitals in adjacent health boards with different protocols. The study included patients aged 16 years and over admitted between 1 July 2009 and 28 Feb 2022. One hospital switched from universal decolonisation of all admissions to targeting only MRSA carriers from 1 February 2019. The other hospital used targeted decolonisation throughout. The researchers analysed rates of S. epidermidis bloodstream infections and tested MRSE and chlorhexidine susceptibility. Results Show Benefits in Reducing Resistant Infections The results, published in The Lancet Microbe , showed that S epidermidis was identified in 334 (45%) of 735 bloodstream infections in the hospital that de-escalated decolonisation. Of these, 197 occurred before de-escalation. Overall, bloodstream infection rates did not increase after de-escalation. However, MRSE infections declined significantly after the switch – from 10.4 to 4.3 cases per 1000 occupied bed days. The probability of MRSE among infections fell from 89.2% to 56.7%. By contrast, the control hospital reported 167 (60%) S. epidermidis bloodstream infections among 278 total, with no significant changes in infection rates or MRSE incidence. Genetic analyses revealed de-escalation was linked to fewer bloodstream infections caused by multidrug-resistant S. epidermidis strains. There was reduced carriage of mobile genetic elements and genes related to multidrug resistance and biofilm production. Balancing Benefits and Risks "In ICU settings with low MRSA incidence, the benefits of universal decolonisation should be balanced against the risks of selecting MRSE sequence types adapted for invasive and device-associated infection," the researchers concluded. Professor Karolin Hijazi, chair in oral and maxillofacial medicine at the University of Aberdeen and study lead, commented in a press release: "This research essentially demonstrates that the excess use of disinfectants in universal decolonisation offered no advantage in terms of control of serious blood infections in a low MRSA ICU setting, but instead caused the unintended rise of MRSE bloodstream infections." Implications for Infection Control Policy The authors recommended that hospitals consider the "unintended harms of universal decolonisation", especially given the global rise of antimicrobial resistance. Hijazi added that such practices increase resistance risks and costs without added benefit in low-MRSA settings. The findings should inform standardised national guidelines for effective and safe patient decolonisation, in line with the government's 5-year action plan for antimicrobial resistance, the researchers said. They described the emergence and spread of antimicrobial resistance as a 'silent pandemic' and stressed that reducing unnecessary decolonisation could help contain resistance and reduce costs.
Yahoo
2 hours ago
- Yahoo
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) and machine learning (ML) technologies to optimise and streamline processes within the drug development landscape, according to speakers from the London biotechnology conference in London, UK, on 18-19 June 2025. In recent years, the pharmaceutical industry has exhibited a significant shift into digitalisation, with AI pushing for innovation across the entire drug development value chain, from accelerating drug discovery to optimising clinical trial design to ultimately improve patient outcomes. Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models. Given the significant costs associated with drug discovery and development, achieving a successful drug candidate remains a major challenge. This complex process involves different processes such as target identification and validation, lead optimisation, and lengthy clinical trials. According to one of Novo Nordisk's speakers at the London Biotechnology conference, the company aims to utilise human data input, such as genetics, samples, and multiomics from a variety of diverse patient populations, into its target discovery engine. The AI-driven engine utilises data mining and analyses linking specific diseases to novel targets to ultimately increase the number of new targets aimed to reach the first human dose. In addition, Novo Nordisk has implemented cell image foundational models driven by deep learning to increase screening throughput derived from extensive sets of genomic data. The usage of AI and deep learning tools within the virtual assay enables large image datasets of cells to be translated into text, allowing effective mapping of the various cells by their morphology, enabling researchers to gain an understanding and effectively predict the characteristics of the cells. The implementation of AI-driven technologies has the potential to streamline many aspects of the drug development value chain, from enabling standardisation of datasets across functionalities to accelerating in vitro and in silico models and tools. As a result, pharmaceutical organisations can scale their methodologies whilst simultaneously increasing output to ultimately improve patient outcomes. "London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
